Emideltide (DSIP): The Nine-Amino-Acid Sleep Peptide With Five Decades of Mixed Evidence Now Facing Its First FDA Compounding Review

Key takeaways

• Emideltide — the regulatory name for delta sleep-inducing peptide (DSIP) — is a nine-amino-acid neuropeptide scheduled for formal FDA Pharmacy Compounding Advisory Committee (PCAC) review on 24 July 2026.
• FDA career scientists publicly recommended against adding it to the Section 503A Bulk Drug Substances List, citing insufficient evidence on effectiveness and safety across all seven peptides under review.
• Human trial data exists but is old, small, and inconsistent; the most controlled studies show modest or statistically ambiguous sleep improvements, while open-label withdrawal data appears more promising.
• Emideltide is not approved by the FDA, MHRA, or EMA; in the UK it has no licensed indication and is sold exclusively as a research-use-only material.
• Even a favourable PCAC recommendation would not authorise compounding: notice-and-comment rulemaking lasting potentially more than a year would still be required.

What Emideltide is and where it came from

DSIP is a neuropeptide first discovered in 1977 by Swiss scientists who isolated it from the cerebral venous blood of rabbits during induced sleep. The peptide — now officially designated Emideltide — consists of nine amino acids and plays a role in regulating sleep architecture and neuroendocrine function.

The name describes the effect observed in early studies: it promotes delta-wave (slow-wave) sleep, the deepest stage of non-REM sleep. In a compounding-pharmacy context it is referred to as Emideltide.

Classification of the peptide is difficult. It is commonly grouped as a neuropeptide or sleep-wake regulatory peptide. It is not a benzodiazepine, non-benzodiazepine hypnotic, orexin antagonist, melatonin agonist, opioid, or approved detoxification medication. It belongs in the "old clinical research / unresolved mechanism" category rather than in the "proven prescription sleep drug" category.

Its mechanism is not fully understood. In research it promotes delta (slow-wave) sleep and appears to interact with stress-response and circadian systems, but the exact receptors and pathways have not been definitively mapped.

The clinical evidence base

Sleep and insomnia

The earliest human data is from a 1981 trial published in the International Journal of Clinical Pharmacology, Therapy, and Toxicology, described in a 2026 review by Innerbody Research. The study found that DSIP injections in six volunteers produced immediate sleep pressure, increased sleep time, decreased sleep onset, and better sleep efficiency without any sedative effects. A subsequent open-label study examined seven patients with severe insomnia given a series of ten DSIP injections. In all but one case, sleep was normalised for follow-up periods of three to seven months.

However, more controlled work yielded weaker findings. A double-blind, crossover polysomnographic trial published in PubMed administered intravenous DSIP or placebo across four nights to chronic insomnia patients. The number of nocturnal awakenings, NREM sleep latency, total waking time, and waking time after sleep onset were decreased under DSIP treatment, but no significant differences were found in comparison to baseline or to double-blind placebo nights. Total sleep time and NREM sleep time were increased by the peptide, related to increases in stage 2, while stage 1, slow-wave sleep, and REM sleep were not modified. The investigators concluded that sleep improvement under DSIP treatment is of little clinical significance.

A parallel-groups double-blind study in 16 chronic insomnia patients found mixed results: the results for objective sleep quality indicated higher sleep efficiency and shorter sleep latency with DSIP compared to placebo, and one measure of subjectively estimated tiredness decreased within the DSIP group. However, data analysis suggested the statistically significant effects were weak and in part could be due to an incidental change in the placebo group. As none of the other measures, including subjective sleep quality, showed any change, it was concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit.

DSIP has more human history than many grey-market peptides, but that history is old, small, and mixed. A few studies explored insomnia, narcolepsy, alcohol withdrawal, and opioid withdrawal.

Opioid and alcohol withdrawal

The withdrawal literature is the more consistent signal in DSIP research. A trial published in European Neurology in 1984, described by Innerbody Research, enrolled approximately 100 inpatients with withdrawal symptoms, each receiving intravenous DSIP. They observed that clinical symptoms of withdrawal disappeared or "improved markedly and rapidly" in 97% of inpatients with alcohol dependence and 87% of those with opiate dependence. Apart from headaches in a few, all patients tolerated the treatment well.

A separate PubMed-indexed trial administered DSIP intravenously to 67 patients presenting withdrawal symptoms — 28 from alcohol, 39 from opiates. From the 49 evaluable patients, DSIP produced a beneficial effect in 48 (22 alcoholics and 26 from 27 opiate addicts), with an immediate onset of action and a good and lasting suspension of somatic symptoms and signs. Anxiety resolved more slowly, within hours. No major side-effect occurred.

Studies reveal DSIP does not bind directly to opioid receptors but acts indirectly through stimulating immunoreactive Met-enkephalin release. This mechanism explains observed analgesic effects and potential applications in addiction research.

Research from Russia and Eastern Europe, where DSIP has been studied more extensively than in the United States, has suggested the peptide may reduce withdrawal symptom severity and improve outcomes in opioid detoxification protocols. The mechanism appears to involve modulation of stress response pathways that are hyperactive during withdrawal.

Narcolepsy

The narcolepsy application is less studied than insomnia or withdrawal. The rationale involves DSIP's apparent role in stabilising sleep-wake architecture. Narcolepsy is characterised by disruption of that architecture, particularly in the transition between wakefulness and REM sleep. In some studies, administration of DSIP has alleviated narcolepsy and normalised disturbed sleeping patterns. The evidence base for this indication is, however, too sparse to support firm conclusions.

Safety profile

The safety and possible side-effects of long-term DSIP use have not been established in clinical research studies. In a 2001 editorial in the European Journal of Anesthesiology, researchers described DSIP as having no lethal dose identified in animal research and no significant side effects beyond transient headache, nausea, and vertigo in humans, according to Innerbody Research. However, the FDA has noted that compounded drugs containing DSIP may pose a risk for immunogenicity. The agency also notes that no safety-related information regarding DSIP has been identified, so it is unknown whether it could be harmful to humans. This is the same immunogenicity concern cited for the other six peptides under PCAC review.

Regulatory status: US

The FDA's updated 503A document, published 15 April 2026, removes Emideltide/DSIP — both free base and acetate forms — from Category 2 and schedules the peptide for PCAC review on 24 July 2026.

The removal from Category 2 followed the withdrawal of the original nominations that had placed it there. It does not, on its own, authorise compounding. Under FDA's current policy, removal of a bulk drug substance from Category 2 does not, by itself, authorise use of that substance in compounding.

Against that backdrop, FDA career scientists posted briefing documents on 30 June 2026 recommending against easing rules for all seven peptides, including Emideltide. The staff scientists determined there was insufficient evidence on the peptides' effectiveness and safety. The reconstituted advisory panel includes several members with financial or professional ties to peptide businesses, raising concerns about conflicts of interest. Many of its members have ties to the peptide industry and work for clinics that offer injectable peptides. One expert in FDA law described the advisory committee as potentially "stacked with people who are known to have certain viewpoints on a topic."

Regardless of the PCAC vote, the PCAC's recommendation is non-binding, and formal rulemaking is what comes next. Even if PCAC recommends adding these peptides to the 503A Category 1 list, and even if FDA agrees, notice-and-comment rulemaking is still required — a process that, under standard timelines, can take more than a year.

The 503B outsourcing facility pathway remains separately unresolved. FDA has been silent concerning Section 503B outsourcing facilities' ability to compound using peptides and has not indicated that these 12 peptides will be reviewed for or otherwise moved to the separate 503B Category 1 list.

Regulatory status: UK and EU

Emideltide holds no licensed status under the MHRA or EMA frameworks. It is not included in any European pharmacopoeia monograph and has no approved product anywhere in the EU or UK. Under UK law, it falls into the "research-use only" category when sold through laboratory suppliers — meaning it may only be used in laboratory or pre-clinical research settings and may not legally be administered to humans outside of a clinical trial authorised by the MHRA. Any UK researcher procuring Emideltide as a research chemical should expect to receive material with variable purity, and should confirm supplier identity, Certificate of Analysis data, and HPLC purity grade before use.

Practical considerations for UK research labs

Emideltide presents particular sourcing challenges. Emideltide is the International Nonproprietary Name (INN) that appears in US regulatory discussions for DSIP — a short peptide historically investigated for sleep and stress-related effects. DSIP has been marketed widely online despite limited modern clinical evidence and an unclear mechanism of action. Researchers should verify that material is labelled by its INN (Emideltide) and that the sequence — Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (nine amino acids) — is confirmed by the supplier's mass spectrometry data.

The grey-market supply chain is active. The Biden administration placed restrictions on these and related peptides in 2023, effectively prohibiting compounding pharmacies from making them. In the years since, peptide users have turned to a grey market, often sourcing the products from sketchy suppliers overseas. The same dynamics apply to research-channel procurement: origin, purity, and storage provenance matter and should be documented.

Outlook

The PCAC meeting on 24 July 2026 will produce a vote, not a determination. For Emideltide specifically, the tension is sharper than for some of its co-reviewed peptides: the withdrawal evidence is suggestive but comes from small, decades-old trials lacking modern placebo controls; the sleep evidence is formally equivocal; and the safety data gap is acknowledged even by the compound's proponents. The outcome of the July advisory meeting may ultimately shape the regulatory pathway for peptides in the US, balancing patient access with safety and evidence requirements. UK labs monitoring the PCAC outcome for procurement-planning purposes should note that any positive US compounding ruling would not automatically confer any change in UK regulatory status.